Lung cancer classification, screening, and staging updates
T h e 2 0 1 5 Wo r l d H e a l t h O r g a n i z a t i o n ( W H O ) classification of tumors of the lung, pleura, thymus and heart has important changes from the 2004 WHO classification (1) . The most significant changes include the use of immunohistochemistry to assist the classification and the use of genetic studies with molecular testing to help personalize the treatment for advanced lung cancer patients. The International Association for the Study of Lung Cancer (IASLC) published the lung cancer staging project of the new T staging for subsolid nodules, as part of the 8 th edition American Joint Committee on Cancer (AJCC) TNM classification (2) . The IASLC has collected an extensive, international database of lung cancer case information from 94,708 patients diagnosed between 1999 and 2010, including tumor sizes, lymph node involvement, and metastasis. The primary tumor categories of adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) were proposed for incorporation into the T (tumor) category for subsolid adenocarcinomas. Accordingly, in the T component of the staging system, the T is category is proposed for AIS, and T1mi is proposed for MIA, recalling that the pathologic microscopic description requires entire-lesion resection (histology) to determine pure lepidic growth in the lesion (AIS) versus minimal invasion (MIA) (3, 4) .
While recommended low dose CT (LDCT) screening criteria continue to be most broadly accepted according to NLST (i.e., active smokers or former smokers with a threshold of 30 pack-years within the past 15 years) using age cutoffs of 55-80 years (5), there is greater recognition of a subset of pure ground-glass lesions that contribute to over-diagnosis (6) , with some controversy as to thresholds for surgical or radio-therapeutic interventions. This notion is especially given risk: benefit considerations with respect to surgical morbidity and mortality weighed against the natural history of such lesions when serial follow-up can be well established in compliant patients. Among ground-glass lesions, appearance and/or growth of a solid component or expansion of any such lesion in the course of followup deserves serious consideration for anatomic surgical resection or curative radiotherapy.
The 8 th edition AJCC TNM classification, which will be published in late 2016 for patients diagnosed with cancer after January 2017, will incorporate advances made in lung cancer research, staging, diagnosis, and treatment since the 7 th edition in October 2009. The revised 8 th edition will have improved precision of staging and newly available therapeutic strategies. A special issue was raised to distinguish between a second primary and a metastasis in patients who have more than one focus in the lungs (7). Currently, clinical and pathologic criteria are used, but no definitive consensus is available.
Lung cancer treatment updates
In the past decade, lung cancer research has provided a variety of new biological insights that impact treatment. Non-small cell lung cancer (NSCLC) can be defined at the molecular level according to the oncogenic mutations, with subsequent application of "personalized" or "targeted" therapies. Other than the successful story of tyrosine kinase inhibitor (TKI) therapy for sensitizing mutations in the epidermal growth factor receptor (EGFR), the anaplastic lymphoma kinase (ALK) inversion/fusion as well The most useful biomarker for predicting responsiveness to date has been tumor expression of the PD-1 ligand PD-L1 (by immunohistochemistry on pathologic sampling) (13) . However, an emerging predictor of responsiveness is the tumor mutagen burden, which is generally higher in squamous carcinoma (likely due to its association with cigarette-induced hyper-mutagenesis), and higher in individuals with higher expression of mutations within the tumor (14) . Moreover, greater neo-antigen (tumor-unique/ non-self epitopes) expression as a result of environmental mutagenesis is a parameter that appears to predict responsiveness to approaches that boost T-cell function.
Other advances in immunotherapy are being realized through novel agents interacting with other immune checkpoint pathways that target multiple ligand-receptor pairs during T-cell receptor engagement with dendritic-or tumor cells. Antibody approaches to inhibit T-cell inhibitory inputs (beyond PD-1 or CTLA-4) or even stimulate with agonisttype antibodies pathways that promote T-effector proliferation (OX-40, 4-1BB, CD27) are under development (15) . Testing of combination therapies within the immunecheckpoint spectrum (e.g., PD1 and CTLA4 blockade) (16, 17) is under investigation, along with considerations of combination with targeted therapies in metastatic lung cancer (e.g., in cases where failure of targeted therapy might not otherwise leave options to improve progressionfree or overall survival) (18) . Adoptive T-cell therapies through ex vivo cytokine-supported expansion and re-infusion into the host, or even the engineering of T cells with chimeric molecules against specific tumor antigens (CAR-T cell therapy) have shown great promise in hematologic malignancies, with ongoing efforts to extend to lung carcinoma and other solid tumors (19) .
